10x Genomics Inc. (TXG)
NASDAQ
63.82
-1.30 (-2.00%)
Closed
Aug 24, 2026
Day's Range
61.0964.37
52 wk Range
11.1665.47
Financial Statements - TXG - 10x Genomics Inc.
Revenue
642.82M▲ 5.2%
Net Income
-43.54M▲ 76.2%Net Margin -6.8%
EBITDA
-45.99M▲ 65.7%
Free Cash Flow
130.11M▲ 2033.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 642.82M | 610.78M | 618.72M | 516.40M | 490.49M | 298.84M |
| Cost of Goods | 198.94M | 196.30M | 209.41M | 120.38M | 74.09M | 58.46M |
| Gross Profit | 443.88M | 414.48M | 409.31M | 396.02M | 416.39M | 240.37M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -110.88M | -194.55M | -204.34M | -167.94M | -52.91M | -85.32M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 50.93M | -1.58M | -61.28M | -198K | -142K | -449M |
| Pre Tax Income | -39.90M | -177.70M | -248.76M | -161.97M | -53.71M | -534.47M |
| Income Tax | 3.63M | 4.92M | 6.33M | 4.02M | 4.50M | 8.25M |
| Net Income | -43.54M | -182.62M | -255.09M | -166M | -58.22M | -542.73M |
| EPS Basic | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 |
| EPS Diluted | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 |
| Basic Shares Outstanding | 124.74M | 120.45M | 117.16M | 113.85M | 110.34M | 101.15M |
| Diluted Shares Outstanding | 124.74M | 120.45M | 117.16M | 113.85M | 110.34M | 101.15M |
| Ebit | -39.90M | -177.69M | -248.73M | -161.49M | -52.84M | -532.79M |
| Ebitda | -45.99M | -133.98M | -144.13M | -128.48M | -25.25M | -63.43M |
| Net Income Continuous Operations | -43.54M | -182.62M | -255.09M | -166M | -58.22M | -542.73M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
